HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CBD Policies From CHPA, CRN Follow FDA; AHPA Acts Ahead Of Agency

Executive Summary

CHPA says FDA's enforcement discretion for hemp and CBD supplements isn't sufficient oversight as potentially unsafe products are available. CRN announces three CBD firms as members, but says "many companies marketing products as containing CBD are not" compliant. Guidance policy adopted in March says AHPA doesn't agree or disagree with FDA but some CBD firms and legal experts assert the agency is "inaccurate, and have presented certain arguments that potentially counter FDA’s position."

Related Content


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts